Wells Fargo & Company MN Sells 122,271 Shares of SciClone Pharmaceuticals, Inc. (SCLN)
Wells Fargo & Company MN decreased its holdings in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) by 67.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 59,221 shares of the specialty pharmaceutical company’s stock after selling 122,271 shares during the period. Wells Fargo & Company MN owned 0.11% of SciClone Pharmaceuticals worth $651,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also bought and sold shares of SCLN. GAM Holding AG purchased a new position in shares of SciClone Pharmaceuticals in the second quarter worth about $4,261,000. Athos Capital Ltd purchased a new position in SciClone Pharmaceuticals during the second quarter valued at approximately $3,126,000. Vanguard Group Inc. grew its stake in SciClone Pharmaceuticals by 9.2% during the first quarter. Vanguard Group Inc. now owns 2,948,846 shares of the specialty pharmaceutical company’s stock valued at $28,899,000 after acquiring an additional 248,785 shares in the last quarter. Marshall Wace North America L.P. grew its stake in SciClone Pharmaceuticals by 1,142.0% during the second quarter. Marshall Wace North America L.P. now owns 242,684 shares of the specialty pharmaceutical company’s stock valued at $2,670,000 after acquiring an additional 223,144 shares in the last quarter. Finally, State of Wisconsin Investment Board purchased a new position in SciClone Pharmaceuticals during the second quarter valued at approximately $2,123,000. Hedge funds and other institutional investors own 72.80% of the company’s stock.
In other SciClone Pharmaceuticals news, CEO Hong Zhao sold 30,000 shares of SciClone Pharmaceuticals stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $11.00, for a total transaction of $330,000.00. Following the completion of the sale, the chief executive officer now directly owns 30,000 shares in the company, valued at $330,000. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Lan Xie sold 10,000 shares of SciClone Pharmaceuticals stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $11.00, for a total transaction of $110,000.00. Following the sale, the vice president now owns 10,000 shares of the company’s stock, valued at $110,000. The disclosure for this sale can be found here. 5.16% of the stock is currently owned by insiders.
SciClone Pharmaceuticals, Inc. (NASDAQ SCLN) opened at $11.15 on Friday. SciClone Pharmaceuticals, Inc. has a 12 month low of $8.55 and a 12 month high of $11.43.
SciClone Pharmaceuticals (NASDAQ:SCLN) last issued its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.24 by $0.02. The company had revenue of $44.52 million during the quarter. SciClone Pharmaceuticals had a net margin of 27.39% and a return on equity of 20.24%.
SciClone Pharmaceuticals Profile
SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.
Receive News & Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.